66 related articles for article (PubMed ID: 8067719)
1. Detection of C-myb genetic alterations and mutant p53 serum protein in patients with benign and malignant colon lesions.
Greco C; Gandolfo GM; Mattei F; Gradilone A; Alvino S; Pastore LI; Casale V; Casole P; Grassi A; Cianciulli AM
Anticancer Res; 1994; 14(3B):1433-40. PubMed ID: 8067719
[TBL] [Abstract][Full Text] [Related]
2. Activation of c-MYC and c-MYB proto-oncogenes is associated with decreased apoptosis in tumor colon progression.
Greco C; Alvino S; Buglioni S; Assisi D; Lapenta R; Grassi A; Stigliano V; Mottolese M; Casale V
Anticancer Res; 2001; 21(5):3185-92. PubMed ID: 11848471
[TBL] [Abstract][Full Text] [Related]
3. C-MYB, serum P-53M, genetic instability, labeling index and endoscopic findings in patients with adenoma or colorectal cancer.
Assisi D; Grassi A; La Penta R; Stigliano V; Greco C; Cianciulli AM; Giannarelli D; Casale V
J Exp Clin Cancer Res; 2004 Sep; 23(3):469-75. PubMed ID: 15595638
[TBL] [Abstract][Full Text] [Related]
4. Oncogene expression in adenocarcinomas of the colon and in colon tumor-derived cell lines.
Untawale S; Blick M
Anticancer Res; 1988; 8(1):1-7. PubMed ID: 3282475
[TBL] [Abstract][Full Text] [Related]
5. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa.
Ramsay RG; Thompson MA; Hayman JA; Reid G; Gonda TJ; Whitehead RH
Cell Growth Differ; 1992 Oct; 3(10):723-30. PubMed ID: 1445802
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of p53 overexpression in human colonic tumors.
Darmon E; Cleary KR; Wargovich MJ
Cancer Detect Prev; 1994; 18(3):187-95. PubMed ID: 8076381
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene.
Wallrapp C; Müller-Pillasch F; Solinas-Toldo S; Lichter P; Friess H; Büchler M; Fink T; Adler G; Gress TM
Cancer Res; 1997 Aug; 57(15):3135-9. PubMed ID: 9242439
[TBL] [Abstract][Full Text] [Related]
8. [IL-6, p53 and proto-oncogene c-myc play different roles as biological markers of plasma cell dyscrasias].
Alvino S; Marcucci M; Canzoniere D; Mosiello A; Del Monte G; Venturo I; Rinaldi M; Gandolfo GM; Lopez M; Greco C
Clin Ter; 1999; 150(3):197-202. PubMed ID: 10528431
[TBL] [Abstract][Full Text] [Related]
9. Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia.
Furihata M; Sonobe H; Ohtsuki Y; Yamashita M; Morioka M; Yamamoto A; Terao N; Kuwahara M; Fujisaki N
J Pathol; 1996 Feb; 178(2):133-9. PubMed ID: 8683378
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations involved in the development of gallbladder carcinomas from Greek patients.
Saetta A; Lazaris AC; Michalopoulos NV; Davaris PS
Hepatogastroenterology; 2001; 48(41):1284-8. PubMed ID: 11677947
[TBL] [Abstract][Full Text] [Related]
11. [Expression and significance of p53, c-erbB2, CEA proteins in colorectal adenoma and carcinoma].
Shu M; Liu S; Yu P
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(2):129-32. PubMed ID: 10681823
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
[TBL] [Abstract][Full Text] [Related]
13. Telomerase activity and p53 gene mutation in familial polyposis coli.
Ikeguchi M; Makino M; Kaibara N
Anticancer Res; 2000; 20(5C):3833-7. PubMed ID: 11268463
[TBL] [Abstract][Full Text] [Related]
14. Apoptotic response to oncogenic stimuli: cooperative and antagonistic interactions between c-myb and the growth suppressor p53.
Sala A; Casella I; Grasso L; Bellon T; Reed JC; Miyashita T; Peschle C
Cancer Res; 1996 May; 56(9):1991-6. PubMed ID: 8616838
[TBL] [Abstract][Full Text] [Related]
15. Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel.
Arber N; Hibshoosh H; Yasui W; Neugut AI; Hibshoosh A; Yao Y; Sgambato A; Yamamoto H; Shapira I; Rosenman D; Fabian I; Weinstein IB; Tahara E; Holt PR
Cancer Epidemiol Biomarkers Prev; 1999 Dec; 8(12):1101-5. PubMed ID: 10613343
[TBL] [Abstract][Full Text] [Related]
16. Protooncogene abnormalities in colon cancers and adenomatous polyps.
Meltzer SJ; Ahnen DJ; Battifora H; Yokota J; Cline MJ
Gastroenterology; 1987 May; 92(5 Pt 1):1174-80. PubMed ID: 3557013
[TBL] [Abstract][Full Text] [Related]
17. c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression.
Thompson MA; Rosenthal MA; Ellis SL; Friend AJ; Zorbas MI; Whitehead RH; Ramsay RG
Cancer Res; 1998 Nov; 58(22):5168-75. PubMed ID: 9823328
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical demonstration of mutant p53 tumour suppressor gene product in aberrant crypt foci.
Stopera SA; Bird RP
Cytobios; 1993; 73(293):73-88. PubMed ID: 8319499
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation.
Kazakov DV; Ivan D; Kutzner H; Spagnolo DV; Grossmann P; Vanecek T; Sima R; Kacerovska D; Shelekhova KV; Denisjuk N; Hillen U; Kuroda N; Mukensnabl P; Danis D; Michal M
Am J Dermatopathol; 2009 May; 31(3):236-47. PubMed ID: 19384064
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
